Liminatus Pharma engages Digital Offering as placement agent for capital raise

Liminatus Pharma Inc. (NASDAQ: LIMN) announced it has entered into an engagement agreement with Digital Offering LLC to serve as its exclusive placement agent for a potential strategic capital raise. Digital Offering is a FINRA- and SEC-registered broker-dealer.

The engagement supports Liminatus's evaluation of a digital asset treasury strategy as the preclinical-stage biopharmaceutical company reviews modern financial tools to strengthen its capital structure. The funding initiative may involve various exempt financing structures, including convertible debentures, equity-linked securities, or other alternative instruments that comply with U.S. securities laws.

Digital Offering will assist the company in sourcing institutional and digital asset-focused investors and structuring a compliant financing solution.

"At Liminatus, our core mission is advancing transformative immunotherapies for cancer," said Chris Kim, CEO of Liminatus. "As we work toward that goal, we are also taking proactive steps to strengthen our capital strategy. Partnering with Digital Offering allows us to explore strategic funding opportunities—both in traditional markets and the evolving digital asset landscape—with discipline and foresight."

The company emphasized that no financing transaction has been finalized and there is no assurance that one will occur. Any potential capital transaction would remain subject to Board of Directors approval and full regulatory compliance.

Liminatus develops immunotherapies for cancer patients and is advancing a pipeline of therapies targeting cancer antigens and tumor-specific immune responses. The company is based in La Palma, California.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Home Depot expands executive roles, grants $500K in restricted stock
• Cytek faces $56M damages award in Beckman Coulter patent case